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Background: Tuberculosis is an infection that requires at least 6 months of chemotherapy in order to clear the
bacteria from the patient’s lungs. Usually, therapeutic monitoring is dependent on smear microscopy where a
decline in acid-fast bacilli is observed. However, this might not be indicative of the actual decline of bacterial
load and thus other tools such as culture and molecular assays are required for patient management.
Case presentation: Here, we report the case of a 12-year-old Black African boy co-infected with tuberculosis and
human immunodeficiency virus who remained smear culture positive and liquid culture negative for a prolonged
period of time following chemotherapy. In order to determine whether there was any live bacteria present in his
specimens, we applied the newly developed molecular bacterial load assay that detects the presence of 16S
ribosomal ribonucleic acid derived from the bacteria. Using this methodology, we were able to quantify his
bacterial load and inform the management of his treatment in order to reduce the disease burden. Following this
intervention he went on to make a complete recovery.
Conclusions: This case report highlights the value of improved biomarkers for monitoring the treatment of
tuberculosis and the role of molecular assays such as the molecular bacterial load assay applied here. The molecular
bacterial load assay detects bacterial ribonucleic acid which corresponds closely with the number of live bacilli as
compared with polymerase chain reaction that detects deoxyribonucleic acid and may include dead bacteria.
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Childhood tuberculosisBackground
Tuberculosis (TB) infection is considered a global health
emergency. In 2013, there were an estimated 9 million
cases of TB, of which 550,000 (6.1 %) were pediatric [1].
Recent modeling work suggests these pediatric estimates* Correspondence: dimitrios.evangelopoulos@crick.ac.uk
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[2]. An estimated 13 % of new TB cases were human
immunodeficiency virus (HIV) positive and 360,000 of
the 1.5 million deaths were in patients who were HIV
positive.
TB-HIV co-infection represents a lethal combination:
the immunodeficiency induced by HIV leads to progres-
sion of TB disease and TB itself decreases the CD4
count and worsens the immunodeficiency caused by
HIV in children [3]. Children with HIV infection are 20
times more likely to develop TB and have a six timesle is distributed under the terms of the Creative Commons Attribution 4.0
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have HIV infection [3]. Anti-retroviral therapy (ART)
has great potential to reduce the risk of TB disease [4].
Diagnosis of TB in patients with HIV is challenging
since the presentation may be nonspecific and the
combination of clinical features and radiological findings
frequently overlap with other common clinical presenta-
tions in HIV. In addition, immunological-based assays
including the tuberculin skin test (TST) and interferon-
gamma release assays may be less sensitive in patients
with HIV [5]. Furthermore, the management of TB-HIV
co-infection is challenging as concurrent administration
of anti-TB therapy (ATT) and ART is associated with
significant drug interactions, potentially limiting their
efficacy [6].
There is an urgent need for development of new
biomarkers that will enable better diagnosis and treat-
ment of TB, particularly in patients with HIV infection.
Childhood TB has historically been neglected but recent
initiatives are currently examining new therapeutics and
novel diagnostic tools specifically for children. One of
the key issues for microbiological diagnosis of TB is
obtaining timely confirmation of the presence of viable
bacteria: culture is slow and can miss specific subpopu-
lations that are viable but non-culturable, whereas myco-
bacterial deoxyribonucleic acid (DNA) persists beyond
the point where there is evidence of viable organisms,
making DNA-based assays unsuitable for monitoring the
decline of live bacteria in clinical samples [7, 8]. We previ-
ously developed a molecular test, the molecular bacterial
load (MBL) assay, based on the detection of mycobacterial
ribosomal ribonucleic acid (RNA) that detects live myco-
bacteria independent of those that are dead [9, 10]. This
assay has been previously used in retrospective studies for
monitoring TB treatment as well as in early bactericidal
assays and it is currently implemented in clinical trials by
the Pan African Consortium for the Evaluation of Antitu-
berculosis Antibiotics. Here we report a case of pediatric
TB-HIV co-infection where the MBL assay, a research
tool, was utilized in real time to gain information
about the disease progression, inform treatment deci-
sions, and monitor treatment compliance.
Case presentation
We present the case of a 12-year-old Black African boy
with perinatally acquired HIV infection and pulmonary
TB. He was born in the United Kingdom (UK) and did
not receive the Bacillus Calmette–Guérin (BCG) vaccine.
He remained clinically well and off ART until 2013 when
he developed recurrent episodes of shingles. At this
time, his CD4 count fell below 500 cells/mm3 for the
first time. He commenced ART with Kivexa® (abacavir/
lamivudine), darunavir, and ritonavir in March 2014. In
July 2014, he presented to his local accident andemergency department (A&E) with a cough associated
with hemoptysis. At this time he reported a 6-month his-
tory of non-productive cough, loss of appetite, and weight
loss. He denied fever and night sweats. He had travelled to
Kenya in 2012 with his family, but had no confirmed con-
tact with individuals with active TB. A sputum sample was
found to have acid-fast bacilli (AFB) on microscopy. A
chest X-ray and computed tomography (CT) scan of his
thorax were indicative of pulmonary TB infection (Fig. 1).
He was transferred to Great Ormond Street Hospital for
Sick Children, National Health Service (NHS) Trust,
London, UK for ongoing care. He was commenced on
ATT with isoniazid, rifabutin, ethambutol, and pyrazina-
mide as per local guidelines. He had no further episodes of
hemoptysis and following review by the thoracic surgeons
and radiologists, it was agreed he did not require interven-
tion at that stage (Fig. 1). The AFB were confirmed to be
Mycobacterium tuberculosis complex and found to be fully
drug sensitive via drug susceptibility testing.
Despite being on an appropriate treatment regimen,
his sputum remained smear positive. In view of this,
repeat resistance testing was performed that did not
show evidence of resistance to first-line therapy. For this
reason, an MBL assay was performed on serial sputum
samples in order to examine the status of the bacilli.
This assay demonstrated that despite a month of
effective therapy there were still detectable numbers
of live bacteria in the sputum samples (Fig. 1). On
the basis of these results, his ATT was modified to
moxifloxacin, isoniazid, pyrazinamide, and ethambutol.
He was discharged home on this regimen under video
observed therapy (VOT) and reviewed regularly by
the Pediatric TB service to ensure compliance with
treatment. Serial sputum samples tested using the
MBL assay over the next 2 weeks demonstrated
declining numbers of live bacteria, despite ongoing
sputum smear positivity (Fig. 1).
He remained clinically well until an out-patient
clinic review 4 weeks later. At this time, he had an
upper respiratory tract infection and a new onset
cough. A sputum sample at this time was smear posi-
tive. He was readmitted and treated with oral co-
amoxiclav for a presumed intercurrent infection.
Nasopharyngeal aspirate and sputum sample testing
did not reveal a virological or bacteriological cause
for this. A repeat chest X-ray showed radiological
improvement (Fig. 1). A further sputum sample sent
3 days later was also smear positive. Both of these
samples were also sent for MBL assay in addition to
mycobacterial culture via the BACTEC MGIT 960
System (Becton Dickinson) and resistance testing. The
MBL assay confirmed a very low bacterial load, ~200
colony-forming units (CFUs), whereas culture and
resistance testing was negative. Clinically he continued to
Fig. 1 The clinical presentation of the patient over time. Three representative X-ray pictures from patient presentation, during therapy, and
follow-up are shown on top of the graph. The time to positivity from culture is reported in days on the left y-axis with black squares. A time to
positivity of 56 is considered to be negative. The molecular bacterial load values are shown on right y-axis as black dots. Smear microscopy is
referred to as acid-fast bacilli positive or acid-fast bacilli negative for positive or negative samples respectively and is shown on the graph as
diamonds. AAFB+ acid-fast bacilli positive, AAFB– acid-fast bacilli negative, CFU colony-forming unit, MBL molecular bacterial load, TTP time to
positivity, ZN Ziehl–Neelsen
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negative (Fig. 1). He has had no further sputum smear or
culture positive results and completed a 9-month treat-
ment course without further incident.Conclusions
In this case of prolonged sputum smear positivity, the
MBL assay was extremely useful both for informing the
decision to change from rifabutin to moxifloxacin and
for following this to confirm mycobacterial response to
the appropriate anti-tuberculous treatment. In addition,
when he presented with renewed sputum smear positivity,
presumably due to mobilization of dead mycobacteria sec-
ondary to a viral-induced cough, the MBL assay provided
reassurance that there was a very low bacterial load in his
sputum samples.
Our patient responded well both clinically and with
decreasing levels of live bacteria as measured by the
MBL assay to a switch in treatment from rifabutin to
moxifloxacin. Last generation fluoroquinolones have
anti-TB bactericidal activity that is comparable with
rifamycins and data from adult patients suggest that
this treatment is efficacious [11]. There are no clinical
trials on the use of these drugs in children, althougha recent pharmacokinetic and safety study for
multidrug-resistant TB in children supports their use
[12]; however, further studies are required before they
can be routinely recommended for drug-sensitive TB.
It is clear that effective treatment monitoring can be
utilized for TB infections and a rapid biomarker such
as the MBL assay, which enables the enumeration of
live mycobacteria in sputum, is vital for appropriate
patient management and to avoid development of
resistance. Since smear microscopy cannot differenti-
ate between live and dead bacilli and some popula-
tions of M. tuberculosis might not be recovered using
microbiological-based culture, a molecular tool that
utilizes bacterial RNA for its detection can identify
accurately the presence of live bacteria in clinical
samples [13]. Our patient had a complete recovery;
however, his last MBL tests constantly exhibited
values of around 200 CFUs (Fig. 1). The significance
of these low numbers of bacteria in the clinical
samples and their potential relevance for causing fur-
ther disease progression or relapse is unclear. One
hypothesis is that the immune system can perhaps
effectively contain these low numbers of bacilli
without any clinical symptoms, but further work is
required.
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